Yes, you may travel with Arava, but keep the medication in its original packaging with the prescription label visible. Carry a copy of your prescription and a letter from your doctor if you are traveling to countries with strict medication import rules.
Both are DMARDs, but leflunomide primarily inhibits pyrimidine synthesis, whereas methotrexate blocks folate metabolism. Their side-effect profiles and monitoring requirements also differ; for example, leflunomide has a higher risk of liver enzyme elevation, while methotrexate is more associated with mucosal ulceration.
If you miss a loading dose (100 mg), take the missed tablet as soon as you remember on the same day and resume the remaining loading doses as scheduled. Do not double-dose the following day.
The tablets should be white to off-white, smooth, and without cracks. Discoloration, powdery surfaces, or broken pieces suggest degradation; discard such tablets and obtain a new supply.
Arava can raise blood pressure in some patients. If you have controlled mild hypertension, your doctor may still prescribe it but will monitor your blood pressure more frequently and may adjust antihypertensive therapy.
Non-steroidal anti-inflammatory drugs (NSAIDs) are often used for symptom relief in rheumatoid arthritis. They can increase the risk of gastrointestinal irritation when taken with leflunomide, so discuss dosage and gastro-protection strategies with your clinician.
Cholestyramine binds teriflunomide in the gut, preventing its re-absorption and accelerating elimination. The standard washout course lasts 11 days and reduces plasma teriflunomide levels to <0.02 µg/mL, allowing safer conception.
Complete avoidance is not mandatory, but excessive alcohol can worsen leflunomide-induced liver toxicity. Moderate consumption (up to one standard drink per day for women, two for men) is generally acceptable, provided liver function is monitored.
Yes, leflunomide is available as a generic medication in 10 mg and 20 mg tablet strengths. Generic products contain the same active ingredient and are subject to the same regulatory standards as the branded version.
Arava is a brand-name medication that contains the active ingredient leflunomide. It belongs to the class of disease-modifying antirheumatic drugs (DMARDs) used in the management of autoimmune conditions. In the United Kingdom Arava is a prescription-only (Prescription Only Medicine, POM) pill marketed by Hikma Pharmaceuticals and regulated by the Medicines and Healthcare products Regulatory Agency (MHRA).
Arava is available in 10 mg and 20 mg tablet strengths. The tablets are round, film-coated, and intended for oral administration with water.
Leflunomide exerts its therapeutic effect by inhibiting the enzyme dihydroorotate dehydrogenase (DHODH). DHODH is essential for the de novo synthesis of pyrimidine nucleotides, which are building blocks of DNA and RNA. By limiting pyrimidine production, leflunomide reduces the proliferation of activated T-lymphocytes and B-lymphocytes-key drivers of autoimmune inflammation.
The drug’s onset of action is typically observed after several weeks, with peak clinical effect emerging around 8-12 weeks of continuous therapy. Leflunomide is well absorbed from the gastrointestinal tract, undergoes extensive first-pass metabolism, and the active metabolite teriflunomide has a long elimination half-life (up to 2 weeks), which contributes to sustained immunomodulation.
Arava is approved by the MHRA for the following indications:
These approvals are based on clinical trials demonstrating reduced joint swelling, improved functional scores, and slowed radiographic progression when leflunomide is added to standard care.
Note: While leflunomide has been investigated for other autoimmune disorders, such uses are not approved in the UK.
Some peer-reviewed studies have explored leflunomide in conditions such as systemic lupus erythematosus (SLE) and multiple sclerosis (MS). Evidence remains limited, and regulatory agencies have not granted approval for these indications.
Disclaimer: Off-label use of Arava should only occur under the direct supervision of a qualified rheumatologist or specialist, with thorough risk-benefit assessment and appropriate monitoring.
These reactions are usually transient and may improve with continued therapy.
Any of the above require immediate medical evaluation and may necessitate drug discontinuation.
Dose adjustments are required for patients with moderate hepatic impairment (reduce to 10 mg daily) or renal dysfunction (use caution; no formal dose reduction recommended but monitor closely).
Prompt reporting of new respiratory symptoms, unexplained fever, or skin eruptions is essential.
This article provides educational information about Arava (leflunomide) and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
